| Literature DB >> 35372360 |
Souradeep Banerjee1, Ritika Nara1, Soham Chakraborty1, Debojyoti Chowdhury1, Shubhasis Haldar1.
Abstract
The pathophysiology of autoimmune disorders is multifactorial, where immune cell migration, adhesion, and lymphocyte activation play crucial roles in its progression. These immune processes are majorly regulated by adhesion molecules at cell-extracellular matrix (ECM) and cell-cell junctions. Integrin, a transmembrane focal adhesion protein, plays an indispensable role in these immune cell mechanisms. Notably, integrin is regulated by mechanical force and exhibit bidirectional force transmission from both the ECM and cytosol, regulating the immune processes. Recently, integrin mechanosensitivity has been reported in different immune cell processes; however, the underlying mechanics of these integrin-mediated mechanical processes in autoimmunity still remains elusive. In this review, we have discussed how integrin-mediated mechanotransduction could be a linchpin factor in the causation and progression of autoimmune disorders. We have provided an insight into how tissue stiffness exhibits a positive correlation with the autoimmune diseases' prevalence. This provides a plausible connection between mechanical load and autoimmunity. Overall, gaining insight into the role of mechanical force in diverse immune cell processes and their dysregulation during autoimmune disorders will open a new horizon to understand this physiological anomaly.Entities:
Keywords: autoimmune diseases; focal adhesion; integrin; mechanical force; tissue stiffness
Year: 2022 PMID: 35372360 PMCID: PMC8971850 DOI: 10.3389/fcell.2022.852878
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
Classification of major integrin with a cluster of differentiation (CD) nomenclature.
| β subunit | α subunit | Integrin name | Classification based on binding site | Classification based on structure | Major ligands | Expression |
|---|---|---|---|---|---|---|
| β1 (CD29) | α1 (CD49a) | α1β1 (VLA-1) | LDV binding | αI domain containing | Laminin, collagen, tenascin | NK cells activated B and T cells |
| α2 (CD49b) | α2β1 (VLA-2) | αI domain containing | Laminin, collagen | NK cells activated B and T cells | ||
| α3 (CD49c) | α3β1 (VLA-3) | XGFFKR sequence containing | Laminin, collagen, fibronectin | Thymocytes and activated T cells | ||
| α4 (CD49d) | α4β1 (VLA-4) | Fibronectin, VCAM1, MAdCAM1, TSP-1 | Monocytes and lymphocytes | |||
| α5 (CD49e) | α5β1 (VLA-5) | RGD specific | Fibronectin, L1 | Macrophages | ||
| α6 (CD49f) | α6β1 | XGFFKR sequence containing | Laminin | T cells (memory and activated), thymocytes | ||
| αv (CD51) | αvβ1 | RGD specific | Vitronectin, fibronectin, collagen, fibrinogen | T regulatory cells | ||
| β2 (CD18) | αL (CD11a) | αLβ2 (LFA-1) | αI domain containing | ICAM1, 2 and 3 | All leukocytes and is predominant in lymphocytes | |
| αM (CD11b) | αMβ2 (Mac-1) | αI domain containing | ICAM1, iC3b, fibrinogen | Especially neutrophils and monocytes also expressed in NK cells, B cells, and some T cells | ||
| αX (CD11c) | αXβ2 | αI domain containing | iC3b and fibrinogen | Myeloid dendritic cells (DCs) | ||
| αD (CD11d) | αDβ2 | αI domain containing | ICAM-3, VCAM1 | Eosinophils, neutrophils, monocytes, and NK cells | ||
| β3 (CD61) | αv (CD51) | αvβ3 | RGD specific | Fibronectin, osteopontin, PE-CAM1, vitronectin, fibrinogen, human L1, thrombospondin, collagen | Monocytes activated B and T cells | |
| αIIb (CD41) | αIIbβ3 | RGD specific | Fibronectin, vitronectin, thrombospondin | Mast cells | ||
| β5 | αv (CD51) | αvβ5 | RGD specific | Vitronectin, fibronectin, fibrinogen | Monocytes and macrophages | |
| β7 | αE | αEβ7 (CD103) | αI domain containing, XGFFKR sequence containing | E-cadherin | Mainly expressed on mucosal T cell | |
| α4 (CD49d) | α4β7 | LDV binding | Fibronectin, VCAM1, MAdCAM-1 | Circulating lymphocytes |
Note. Classification of the integrin subtypes with structural features and/or their binding sites on respective ligand molecules. Classification is based on data from (Dickeson and Santoro, 1998; Humphries et al., 2006; Barczyk et al., 2009; Bachmann et al., 2019). CD nomenclatures are according to the Human Cell Differentiation Molecules (https://www.hcdm.org/).
CD, cluster of differentiation; LDV, a motif of some integrin ligands; RGD, a motif of the majority of integrin ligand; αI domain, a chordate specific domain in the α subunit of integrin; XGFFKR, a sequence present in the proximal cytoplasmic tail of integrin α subunit where X is a variable amino acid.
FIGURE 1Integrin-dependent mechanotransduction by outside-in and inside-out signaling. Integrin can exist between three conformational states: bent-closed, extended-closed, and extended-open conformation. Bent-closed conformation is functionally inactive and thus could not interact with cell–extracellular matrix (ECM) ligands. Chemokine signaling initiates RIAM to bind the autoinhibited talin. The autoinhibited talin–RIAM complex binds to the Rap1 protein, which activates talin by extending it from the autoinhibited structure. Subsequently, the extended talin binds to the NPxY motif of the cytosolic tail of the β subunit of integrin. Talin binds to PIP2 by the FERM domain (red pentagon) and actin by its actin-binding domains. These interactions break the transmembrane salt bridge between α and β subunits and activate integrin by providing the required force, which allows integrin to cross its internal thermodynamic barrier, resulting in the active state stabilization by the very low force provided by talin. Now activated integrin is able to bind ECM ligands on the extracellular region connected to the actomyosin complex inside the cell. On the contrary, integrin also gets activated from the extended-closed structure through outside-in force sensing by forming interacting bonds with its intercellular ligands like CAMs or ECM proteins. The thermodynamic barrier causes conformational fluctuation between the most stable bent-closed to unstable extended-open conformation through a transient extended-closed state. While experiencing ligands outside the cell, the extended-closed conformation has the ability to form a transient bond with the ligand (here CAM), which transmits the force through integrin to talin. Talin along with PIP2 breaks the transmembrane salt bridge, activating the integrin to extended-open conformation. This is followed by the binding of the actin cytoskeleton to talin. This provides longer and more durable catch-bond formation, under force, between the integrin-extracellular ligand, thus transducing the signaling cascades and retrograde flow to regulate immune synapse formation, activation of lymphocytes, tissue invasion by migration, cytotoxicity, etc. (Orłowski et al., 2015b; Haining et al., 2016; Yao et al., 2016; Khan and Goult, 2019; Sun et al., 2019).
FIGURE 2Integrin-mediated immune cell adhesion to endothelial cells under a shear force of blood flow. (A) Migration of immune cells under force—immune cells traveling through the blood vessel experience a shear force of the blood flow. Chemokines (green) are secreted by the endothelial cells lining the tissue displaying self-antigens; however, the chemokine gradient is highest near the infectious tissue. The chemokines slow down the flow rate of the migratory leukocytes towards the site of infection under the shear stress of blood flow, equivalent to 1 dyn/cm2. (B) Slip-bond formation and decrement in cell migration velocity—cells gradually decrease the speed along with the rise of chemokine gradient and tumble on the endothelial cells of the blood vessel. The selectin molecules, expressed by the leukocyte, interact with its counterpart expressed on the endothelial cells. However, their interaction under a shear force of blood flow causes the slippage of the bonds, allowing the cell to roll on the endothelial layer, while rolling numerous numbers of slip bond forms and breaks between the molecules like P-selectin, E-selectin, PSGL1, E-cadherin, etc. (C) Extended-closed integrins—the GPCR expressed on the leukocytes interacts with the chemokine to activate PI3K that induces Rap1–RIAM complex to activate talin for further binding with the β subunit cytosolic tail of integrin. This partially activates integrin from its bent-closed to extended-closed structure. (D) Integrin activation leading to focal adhesion—the extended-closed integrin gets activated, either by outside-in signaling by interacting with CAM while rolling on the endothelial layer or by inside-out signaling through sensing the force from talin–actin complex. The activation breaks the integrin salt bridge, transforming it into a thermodynamically unstable but active extended-open conformation. This forms integrin–ligand catch bonds under blood-flow shear force, resulting in complete adhesion of the immune cells to the endothelial layer. During this interaction, the force is transmitted through integrin both outside and inside the cell, which finally transduces downstream forming the focal adhesion. (E) Adhesion of cell—this focal adhesion regulates the cell's shape and migration and strictly adheres the cell on the endothelial layer by inducing the catch-bond formation. (F) Diapedesis—while remaining attached on the endothelial surface in the infected tissue, the self-reactive immune cells transmigrate in between adjacent cells by diapedesis towards the infected tissue region (Zhu et al., 2007b; Jahed et al., 2014; Huse, 2017).
Integrin–ligand interaction playing regulatory roles in immune cells processes.
| Immune processes | Integrin types | Integrin–ligand interactions | Force quantified in these interactions | References |
|---|---|---|---|---|
| Lymphocyte migration | α4β1 (VLA-4) | α4β1/VCAM1 | ∼50 pN |
|
| AFM-based study [10 pN/s ( | ||||
| αLβ2 (LFA-1) | αLβ2/ICAM1 | 10–15 pN |
| |
| Biomembrane force probe-based study | ||||
| Eosinophil adhesion | αDβ2 | αDβ2/VCAM1 | NA |
|
| Monocyte migration | αDβ2 | NA | NA |
|
| Lymphocyte homing | α4β7 | α4β7/ MAdCAM1 | 32–80 pN |
|
| AFM-based study (100–1,500 pN/s) | ||||
| Macrophage differentiation | α5β1 | α5β1/fibronectin | 10–30 pN |
|
| AFM-based study | ||||
| T-lymphocyte adhesion | αLβ2 (LFA-1) | αLβ2/ICAM1 | 10–15 pN |
|
| Biomembrane force probe-based study | ||||
| αEβ7 | αEβ7/E-Cadherin | 60 pN |
| |
| AFM-based study | ||||
| Macrophage adhesion | α5β1 | α5β1/Fibronectin | 10–30 pN |
|
| AFM-based study | ||||
| αDβ2 | αDβ2/vitronectin | NA |
| |
| Formation of immunological synapse (IS) or supramolecular activation cluster (SMAC) in T cell | αLβ2 (LFA-1) | αLβ2/ICAM | 10–15 pN of biomembrane force probe-based study |
|
| B-cell adhesion, activation, and synapse formation | αLβ2 (LFA-1) | αLβ2/ICAM1 | 10–15 pN |
|
| Biomembrane force probe study | ||||
| Neutrophil crawling | αMβ2 (Mac-1) | αMβ2/ICAM1 | 10 pN |
|
| Biomembrane force probe-based study | ||||
| Monocyte and platelet adhesion | αMβ2 | αMβ2/CD147 | NA |
|
| Inflammatory response | αMβ2 α4β1 | αMβ2/pleiotrophin | NA |
|
| AFM-based study (10 pN/s ( | (VLA-4) | α4β1/VCAM1 | ∼50 pN |
|
| Complement activation | αMβ2 | αMβ2/iC3b | NA |
|
| αXβ2 | αXβ2/iC3b | NA |
|
FIGURE 3Regulatory role of force during lymphocyte activation in immune synapse—during T lymphocyte activation (green), it interacts with an antigen-presenting cell (APC; blue) to recognize the antigen, presented by the APC. During this binding, there form three regions: central regions of supramolecular activation complex (cSMAC), peripheral SMAC (pSMAC), and distal SMAC (dSMAC). TCR/peptide–MHC interaction occurs in the cSMAC region and is required for the T-cell activation, whereas force-dependent integrin–ligand (LFA-1/ICAM1) interactions take place in the pSMAC region, which surrounds the inner cSMAC region. This results in the formation of focal adhesion complexes inside the lymphocyte at the immunological synapse. This integrin interaction at the pSMAC plays a crucial role in the co-stimulation of T-cell activation by forming adhesome enriched with talin bounded actin–myosin complex. Additionally, the interaction between TCR-antigen–MHC complexes in the cSMAC also occurs under force and forms catch bonds up to ∼10 pN (Huse, 2017).
Integrin and its ligands as a key contributor in the progression of autoimmune diseases
| Disease | Integrins involved | Immune cells involved | Integrins role in autoimmune disease |
|---|---|---|---|
| Systemic lupus erythematosus (SLE) | Mac-1 (αMβ2) | B cells, neutrophils, and macrophages express high amount of αMβ2 ( | • Mac-1 deficiency study induces hyper-immune response in SLE-prone mouse model ( |
| • Non-synonymous mutation in Mac-1 gene ITGAM causes “R77H” mutation in the β propeller domain. This results in decreased catch-bond formation with ligand under shear force ranging from 0.19 to 0.42 dyn/cm2 and is directly associated with SLE. Most significant difference was observed at 0.32 dyn/cm2 ( | |||
| • Mac-1 promotes neutrophil accumulation in anti-glomerular basement nephritis by bearing the FcγR–IgG-mediated adhesion of neutrophils. | |||
| Crohn’s disease (CD)- | α4β1 (VLA‐4) and α4β7, αEβ7 | NK cells, T and B lymphocytes, neutrophils | • CD is caused due to infiltration of leukocytes in the gastrointestinal tract with the help of α4β7-MadCAM1 ( |
| • Leukocytes can also be independently helped by α4β1/VCAM1 to transmigrate into the intestinal tract ( | |||
| • αEβ7 expressing CD4+ T memory cells may be a major cause of inflammation due to CD, as αE+ T cells are known to destroy intestinal epithelial cells and are responsible for site-specific migration ( | |||
| Ulcerative colitis (UC)- | αEβ7, α4β1 and α4β7 | CD4+ T cells, TH1, and TH17 cells | • VCAM1 and MAdCAM1 are expressed highly in intestinal cells of UC patients, guiding α4β1 and α4β7 expressing cytotoxic and pro-inflammatory T cells into lamina propria |
| • Inside lamina propria, T lymphocytes are retained by interaction between αEβ7 and E-cadherin of intestinal epithelia ( | |||
| Type 1 autoimmune hepatitis | α4β7 | CD4+ and CD8+ T cells, NK cells, γδT cells | • α4β7 integrin and CCR9 chemokine receptor-expressing T cells are generally not expressed much in liver cells. However, patients with IBD display MAdCAM1 and CCL25, ligands for α4β7 and CCR9, in their liver tissue. This causes the T lymphocytes, expressing α4β7 and CCR9, to migrate to liver from gut where any expression of auto-antigen either from gut or liver can cause immune response causing AIH ( |
| Scleroderma | αVβ3, α5β1 and αVβ6 Mac-1 (αMβ2) | Macrophage, monocyte, B lymphocyte and T lymphocyte | • Fibrillin-1 is an ECM component that interacts with αVβ3, α5β1, and αVβ6 with its RGD-binding domain ( |
| • Missense mutation of fibrillin-1 RGD domain, which interacts with integrin, can cause aggressive skin fibrosis ( | |||
| • Disruptive cell–matrix interaction can cause upregulation of integrins, which can further be targeted as therapeutic agents ( | |||
| • αM encoding gene ITGAM variant rs1143679 is linked with susceptibility towards systemic scleroderma ( | |||
| • MiR-150 regulates β3 integrin expression, which gets downregulated in lesions of systemic scleroderma ( | |||
| • Additionally, αVβ6-induced TGF-β expression can cause apoptosis resistance in fibroblasts ( | |||
| Psoriasis | α1β1 α6 integrin | T lymphocyte | • Inhibition of α1β1 to interact with collagen causes reduced accumulation of epidermal T cells. This has been observed with prevention of psoriasis ( |
| • Integrity of laminin changes in psoriatic skin, causing insufficient interaction with α6 integrin ( | |||
| • Hence, autoantibodies developed against α6 integrin cause the micro-wounds in skin ( | |||
| Dermatomyositis | αVβ3 | Monocytes, T lymphocytes, and B lymphocytes | • Neovascularization was increased in muscle biopsies of dermatomyositis juvenile patients ( |
| • mRNA profiling showed upregulation of angiogenesis-related factors in dermatomyositis biopsies | |||
| • Integrin αVβ3 assists in neovascularization, and its expression is higher in juvenile patients affected by dermatomyositis ( |
FIGURE 4Schematic diagram of type 1 diabetes mellitus (T1DM) pathophysiology and its regulation by integrin: the figure provides a schematic diagram of how autoimmune diabetes mellitus causes and integrin regulates this disease. Blue arrows denote signaling/mechanism being regulated by integrin.
FIGURE 5Schematic diagram of rheumatoid arthritis pathophysiology: the figure provides a schematic diagram of how rheumatoid arthritis develops and what points of this disease are regulated by integrin. Blue arrows denote signaling/mechanism being regulated by integrin.
FIGURE 6Schematic diagram of multiple sclerosis pathophysiology and role of integrin in its progression: the figure provides a schematic diagram of how multiple sclerosis develops and what points of this disease are regulated by integrin. Blue arrows denote signaling or mechanism being regulated by integrins.
FIGURE 7Schematic diagram of vitiligo pathophysiology: the figure provides a schematic diagram of how vitiligo develops and what points of this disease are regulated by integrin. Blue arrows denote signaling or mechanism being regulated by integrins.
FIGURE 8Plausible correlation between the worldwide prevalence of different autoimmune disorders with organ stiffness: the prevalence percentage of different autoimmune disorders affecting differentially stiff organs has been illustrated. Autoimmune diseases range from autoimmune encephalitis, type 1 diabetes mellitus (T1DM), and autoimmune thyroiditis, which affects softer tissues like the brain, pancreas, and thyroid, respectively, to vitiligo, psoriasis, multiple sclerosis, and lupus scleroderma, which affect stiffer or hard tissues, have been considered for this study. As the figure depicts, the trend of autoimmune disease prevalence shows a positive correlation with the different organ stiffness. For example, in the case of autoimmune thyroiditis, the worldwide prevalence rate is approximately 0.1%, which majorly affects the thyroid with tissue stiffness of 29 kPa (Guimarães et al., 2020), whereas, with lupus, which affects ligament (>5 MPa), the prevalence rate increases to 0.8%. Autoimmune encephalitis affected the brain; type 1 diabetes mellitus affected the pancreas; Hashimoto’s thyroiditis affected the thyroid; multiple sclerosis and ankylosing spondylitis affected the spinal cord; vitiligo, psoriasis, and scleroderma affected the skin; relapsing polychondritis and rheumatoid arthritis affected the cartilage; rheumatoid arthritis and lupus affected the ligament (Chopra et al., 2013; Baldini et al., 2017; Resende de Paiva et al., 2017; Dubey et al., 2018; Parisi et al., 2020; Siebert, Raj, Tsoukas; Walton et al., 2020; Almutairi et al., 2021; Barber et al., 2021).